Steve Witt named CEO of OptiEnz Sensors to Accelerate Company To Commercialization 

Colorado BioScience Association Applauds signing of The Colorado Advanced Industries Acceleration Act (HB 1001) by Gov. John Hickenlooper 

SomaLogic® technology used to discover protein that reverses age-­related cardiac hypertrophy in mice  

Nature Biotechnology- A new study assesses the impact of recent US Supreme Court rulings on the changing landscape of US patents claiming nucleic acids. 

OSAKA, Japan and DEERFIELD, Ill. and FORT COLLINS, Colo., May 7, 2013 /PRNewswire via COMTEX/ -- Takeda Pharmaceutical Company Limited ("Takeda") and Inviragen, Inc. ("Inviragen") jointly announced today that Takeda, its wholly owned subsidiary Takeda America Holdings, Inc., and Inviragen, Inc. have entered into a definitive agreement for Takeda to acquire Inviragen for an upfront payment of US$35 million, and future payments of up to US$215 million linked to the progress of clinical development and achievement of key commercial milestones. Headquartered in Fort Collins, CO, with facilities in Madison, WI and Singapore, Inviragen is a privately-held biopharmaceutical company specializing in research and development of innovative vaccines for emerging infectious diseases, including dengue and hand, foot and mouth disease (HFMD). 

Ultrasound Transducer Field Analysis and Acoustic Pressure-Mapping System 

BOULDER – The delivery of drugs into the body through infusion therapy is one of the cornerstones of medicine, as most anyone who’s been hospitalized can attest. 

DBJ: A proposal that would’ve let pharmacists substitute generic biotech drugs for name-brand drugs prescribed to patients has died a quiet death in the state Legislature. 

BCBR: DENVER - Derek Cole was appointed chairman of the board of the Colorado BioScience Association at the trade group's annual meeting Wednesday.